九典制藥(300705.SZ):預計2025年將獲批吲哚美辛凝膠貼膏和氟比洛芬凝膠貼膏
格隆匯11月8日丨九典制藥(300705.SZ)於2024年11月8日接受特定對象調研,就“公司未來其他凝膠貼膏產品上市節奏?”,公司表示,目前,消炎解痛巴布膏預計從本月開始上市銷售;按照現在的研發進展和產品申報情況,預計2025年將獲批吲哚美辛凝膠貼膏和氟比洛芬凝膠貼膏。預計2026年獲批的外用製劑有洛索洛芬鈉貼劑、酮洛芬貼劑、氟比洛芬貼劑、克立硼羅軟膏、雙氯芬酸二乙胺乳劑、鹽酸丁卡因凝膠。除了自主研發,公司也會加大外用製劑的收購力度,儘快構建產品矩陣,充分發揮銷售網絡優勢,進一步鞏固公司外用製劑的市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.